04.27.15
Swedish pharma firm Moberg Pharma AB has acquired Balmex from Chattem, Inc., the US consumer healthcare division of Sanofi. The purchase price was $3.9 million, according to Moberg Pharma.
According to IRI data for the 52 weeks ended Dec. 28, 2014, sales of Balmex baby ointments/creams fell 11% to $4.95 million.
Swedish pharma firm Balmex will be sold through Moberg’s current OTC channel in the US, primarily in chain drugstores, such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart as well as specialty retailers including Toys R’ Us and buybuyBABY. Mainy known as a diaper rash treatment line, Chattem added an adult Balmex line for soothing skin irritations in 2013.
“Adding Balmex to Moberg’s U.S. portfolio is a great fit, within our core area of topical dermatology,” noted said Peter Wolpert, CEO of Moberg Pharma AB. “We are continuously evaluating deal opportunities to further leverage our U.S. sales and marketing infrastructure."
Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal and Kerasal Nail, nail treatments, topical pain relief cream Jointflex, skin treatment Domeboro as well as Vanquish and Fergon ingestibale remedies.
According to IRI data for the 52 weeks ended Dec. 28, 2014, sales of Balmex baby ointments/creams fell 11% to $4.95 million.
Swedish pharma firm Balmex will be sold through Moberg’s current OTC channel in the US, primarily in chain drugstores, such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart as well as specialty retailers including Toys R’ Us and buybuyBABY. Mainy known as a diaper rash treatment line, Chattem added an adult Balmex line for soothing skin irritations in 2013.
“Adding Balmex to Moberg’s U.S. portfolio is a great fit, within our core area of topical dermatology,” noted said Peter Wolpert, CEO of Moberg Pharma AB. “We are continuously evaluating deal opportunities to further leverage our U.S. sales and marketing infrastructure."
Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal and Kerasal Nail, nail treatments, topical pain relief cream Jointflex, skin treatment Domeboro as well as Vanquish and Fergon ingestibale remedies.